Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia

Vaccine

Volumn 31, Issue 12, 2013, Pages 1641-1645

  Ventura, Roland ^a   Brunner, Livia ^a   Heriyanto, Bambang ^b   De Boer, Otto ^c   O'Hara, Michael ^d   Huynh, Chuong ^d   Suhardono, Mahendra ^b   Collin, Nicolas ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Bio Farma   (Indonesia)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Oil in water adjuvant; Pandemic influenza vaccine; Technology transfer; Vaccine formulation

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; SQUALENE; WATER OIL CREAM;

ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDONESIA; INFLUENZA A (H5N1); LABORATORY; LIGHT SCATTERING; PANDEMIC INFLUENZA; PH; PILOT STUDY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY CONTROL; SEASONAL INFLUENZA; TECHNOLOGY; UNITED STATES; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; DEVELOPING COUNTRIES; FACILITY REGULATION AND CONTROL; INDONESIA; INFLUENZA VACCINES; INTERNATIONAL COOPERATION; QUALITY CONTROL; SQUALENE; TECHNOLOGY TRANSFER; TECHNOLOGY, PHARMACEUTICAL;

EID: 84875253241     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.074     Document Type: Article

References (14)

1. Collin N., Dubois P.M. The Vaccine Formulation Laboratory: a platform for access to adjuvants. Vaccine 2011, 29(Suppl. 1):A37-A39.
2. Friede M., Palkonyay L., Alfonso C., Pervikov Y., Torelli G., Wood D., et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011, 29(Suppl. 1):A2-A7.
3. Suhardono M., Ugiyadi D., Nurnaeni I., Emelia I. Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia. Vaccine 2011, 29(Suppl. 1):A22-A25.
4. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO 2012. Available from: [cited 01.05.12]. http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html.
5. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006 Mar 30, 354(13):1343-1351.
6. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(August(9587)):580-589.
7. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6(October(5)):699-710.
8. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008, 26(March(12)):1525-1529.
9. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Senatore F., Minutello M., et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001, 17(2):135-140.
10. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2(January(15)):15ra5.
11. Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G., Vedvick T.S. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011, 29(November(51)):9563-9572.
12. Frey S., Poland G., Percell S., Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003, 21(October(27-30)):4234-4237.
13. Ott G., Radhakrishnan R., Fang J.-W., Hora M. The Adjuvant MF59: a 10-year perspective. Vaccine adjuvants: preparation methods and research protocols 2000, 211-228. M. Medicine (Ed.).
14. Friede M., Serdobova I., Palkonyay L., Kieny M.P. Technology transfer hub for pandemic influenza vaccine. Vaccine 2009 Jan 29, 27(5):631-632.